Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Review.

PMID:
23223420
2.

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis.

Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, Bardales R, Elashoff D, Vangala S, Furst DE.

BioDrugs. 2015 Aug;29(4):241-58. doi: 10.1007/s40259-015-0134-5. Review.

PMID:
26280210
3.

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.

Maneiro JR, Salgado E, Gomez-Reino JJ.

JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430. Review.

PMID:
23797343
4.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

5.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334.

PMID:
23032984
6.

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.

Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A.

BMC Musculoskelet Disord. 2008 Apr 17;9:52. doi: 10.1186/1471-2474-9-52. Review.

7.

Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.

Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O.

J Rheumatol. 2015 Jan;42(1):73-8. doi: 10.3899/jrheum.140685.

PMID:
25399390
8.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341.

PMID:
22563743
9.
10.

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E.

Clin Rev Allergy Immunol. 2010 Apr;38(2-3):82-9. doi: 10.1007/s12016-009-8140-3. Review.

PMID:
19565360
11.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

12.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
13.

Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.

Moss AC, Brinks V, Carpenter JF.

Aliment Pharmacol Ther. 2013 Nov;38(10):1188-97. doi: 10.1111/apt.12507. Review.

16.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register..

Rheumatology (Oxford). 2006 Dec;45(12):1558-65.

PMID:
16705046
17.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
18.

Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.

Marinari B, Botti E, Bavetta M, Spallone G, Zangrilli A, Talamonti M, Richetta A, Chimenti S, Costanzo A.

Drug Dev Res. 2014 Nov;75 Suppl 1:S11-4. doi: 10.1002/ddr.21186.

PMID:
25381966
19.

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.

Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T.

Scand J Rheumatol. 2007 Nov-Dec;36(6):411-7. Review.

PMID:
18092260
20.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Collamer AN, Battafarano DF.

Semin Arthritis Rheum. 2010 Dec;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003. Review.

PMID:
20580412
Items per page

Supplemental Content

Support Center